Browse the corpus

Bivalirudin, a direct thrombin inhibitor, plays a crucial role in the management and treatment of patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction. This comprehensive activity delves into the nuanced aspects of bivalirudin therapy, shedding light on its indications, action, and contraindications. Beyond bivalirudin's established role in PCI, this session explores the broader applications of bivalirudin in thromboembolic disease, cardiopulmonary bypass, and extracorporeal membrane oxygenation. Participants will gain an in-depth understanding of the drug's mechanism of action, adverse event profile, off-label uses, dosing, monitoring parameters, contraindications, and potential drug interactions, empowering them to navigate the complexities of managing patients undergoing PCI and other related conditions. This educational initiative equips healthcare professionals with the competency to manage diverse aspects of bivalirudin therapy. Objectives: Screen patients for potential contraindications or increased bleeding risk factors that may affect the selection and dosing of bivalirudin as an anticoagulant during PCI. Differentiate the pharmacological properties, mechanism of action, and safety profile of bivalirudin from other anticoagulant agents used in PCI, including unfractionated heparin or low molecular weight heparin. Select the most appropriate anticoagulant strategy, including the decision to use bivalirudin as a monotherapy or in combination with other antithrombotic agents, based on individual patient factors and the clinical scenario. Determine strategies with interventional cardiologists, anesthesiologists, and other healthcare team members to ensure coordinated care, appropriate dosing, and monitoring of bivalirudin during PCI procedures. Access free multiple choice questions on this topic.

The toxic effects related to bivalirudin administration primarily pertain to bleeding. No minimum toxic dose is listed; complications can occur at therapeutic doses. In a study by Gleason et al, the no-observed-adverse-effect level (NOAEL), administered to rats intravenously over 24 hours, was 2000 mg/kg/24 h.[33] Bivalirudin has been used in the pediatric and infant populations, but there is not enough data to recommend dosing adjustments in pediatric patients.[34][35] Approximately 1.4% to 3.8% of patients will develop significant hemorrhage. Reports exist of intracranial bleeding, retroperitoneal bleeding, and clinically overt bleeding in patients undergoing PCI to treat unstable angina. This risk increases with the concomitant use of aspirin and streptokinase.[36] In most patients, the primary bleeding site was at the catheterization site. In the event of bleeding, evaluating the need for anticoagulation and deciding to reduce or discontinue the infusion requires clinical judgment. Appropriate monitoring includes a CBC, prothrombin time (PT), aPTT, and international normalized ratio (INR). Note that there may be variable responses with these values. Since bivalirudin excretion is primarily via the kidneys, the patient's renal function requires monitoring. Supportive care is recommended, including a fluid bolus and transfusion of platelets or packed red blood cells in thrombocytopenic/anemic patients. In patients with continued bleeding, fresh frozen plasma, prothrombin complex concentrations, and cryoprecipitate may merit consideration. Note that this comes with an inherent risk of developing thromboembolic events. There is no reversal agent available for bivalirudin.

Bivalirudin has proven to be an effective anticoagulant used by interventional cardiologists during PCI in patients with acute coronary syndrome. The drug is also an ideal anticoagulant in patients with a history of HIT and has predictable pharmacologic effects. As bivalirudin use increases, its applications have broadened to include patients who require anticoagulation on cardiopulmonary bypass, ECMO, and deep venous prophylaxis. Given that patients receiving bivalirudin will be in the hospital setting, overdose is rare. Despite this, a multidisciplinary approach to monitoring such patients is necessary. Interprofessional team communication and monitoring and prescribing activity coordination between proceduralists, physicians, pharmacists, and nurses are necessary to ensure optimal patient outcomes. Evaluation begins with the appropriate monitoring of patients, including careful assessment at the bedside. The healthcare team must maintain a high degree of clinical vigilance, as the clinical manifestations of bleeding may be confounded by other comorbidities in patients receiving bivalirudin. Patients should be monitored for hypotension, tachycardia, and oozing at IV sites should be sought out, to check for bleeding. A hematologist consultation is required for heparin-induced thrombocytopenia.[7] Laboratory evaluation and imaging studies may be warranted. As a guideline for therapeutic response, the aPTT is the most commonly used metric. Dosing regimens should then be adjusted accordingly by a pharmacist and ordering clinician. Dosing protocols have been developed for monitoring bivalirudin therapy and are usually specific to the institution. Interprofessional care coordination and communication among clinicians and pharmacists achieve the best patient outcomes with the fewest adverse reactions.